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Abstract Huntington’s disease (HD) is a neurodegener-
ative disorder caused by a polyglutamine expansion near
the N-terminus of huntingtin. A neuropathological hall-
mark of Huntington’s disease is the presence of intracel-
lular aggregates composed of mutant huntingtin N-terminal
fragments in human postmortem brain, animal models, and
cell culture models. It has been found that N-terminal
fragments of the mutant huntingtin protein are more toxic
than the full-length protein. Therefore, proteolytic pro-
cessing of mutant huntingtin may play a key event in the
pathogenesis of HD. Here, we present evidence that the
region in huntingtin covering amino acids 116 to 125 is
critical for N-terminal proteolytic processing. Within this
region, we have identiﬁed mutations that either strongly
reduce or enhance N-terminal cleavage. We took advan-
tage of this effect and demonstrate that the mutation
D121–122 within the putative cleavage region enhances
N-terminal cleavage of huntingtin and the aggregation of
N-terminal fragments. Furthermore, this particular deletion
increased the activation of apoptotic processes and
decreased neuronal cell viability. Our data indicate that the
N-terminal proteolytic processing of mutant huntingtin can
be modulated with an effect on aggregation and cell
death rate.
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Introduction
Huntington’s disease (HD) is an autosomal-dominant
inherited, progressive and fatal neurodegenerative disorder
caused by expansion of a CAG repeat in the huntingtin
gene, coding for polyglutamine (polyQ) (The Huntington’s
Disease Collaborative Research Group 1993; Ross et al.
1997). The expansion of the polyQ stretch in the huntingtin
protein (htt) to a length greater than 36 consecutive glu-
tamines is causing HD. The onset of disease usually occurs
in mid-adult life and lasts 15–25 years. Symptoms of HD
include involuntary movements, cognitive impairment, and
psychiatric disturbances (Vonsattel and DiFiglia 1998).
Despite widespread expression of the huntingtin gene
(Sharp et al. 1995), there is a selective vulnerability and
loss of the medium spiny projection neurons in the striatum
(Vonsattel et al. 1985).
Transgenic or knock-in mice that express full-length or
truncated mutant htt (mhtt) display a neurological pheno-
type resembling HD with intracellular inclusions (Davies
et al. 1997; Hodgson et al. 1999; Reddy et al. 1998;
Schilling et al. 1999; Tanaka et al. 2006; Wheeler et al.
2000). Postmortem analysis of brains from HD patients and
studies using mouse or cell culture HD models revealed
that nuclear and cytoplasmic inclusions contain N-terminal
fragments of mhtt (DiFiglia et al. 1997; Gutekunst et al.
1999; Lunkes et al. 2002; Schilling et al. 2007). Moreover,
pathological changes are accelerated in HD mouse models
overexpressing mhtt N-terminal fragments compared to
those with full-length mhtt (Hodgson et al. 1999;
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2000). One exception is observed with the HD mouse
model expressing the ﬁrst 117 amino acids (aa) of mhtt
showing neuronal inclusions but no behavioral abnormal-
ities or neurodegeneration (Slow et al. 2005). Since the
correlation between formation of inclusions and neuronal
cell death is weak (Gutekunst et al. 1999; Kuemmerle et al.
1999; Saudou et al. 1998), the role of inclusions in HD
pathogenesis is not clear. Accumulated evidence suggest
that the oligomeric intermediates of mhtt fragments cause
cytotoxicity (Arrasate et al. 2004; Ross and Poirier 2005;
Sanchez et al. 2003).
Htt can be cleaved between residues 400 and 600 at
several sites by caspases, calpains, and MMP-10 (Gafni
and Ellerby 2002; Goldberg et al. 1996; Kim et al. 2001;
Miller et al. 2010; Wellington et al. 2002), which may
contribute to toxicity (Gafni et al. 2004; Graham et al.
2006; Wellington et al. 2000). In addition, smaller N-ter-
minal fragments of htt than those generated by caspase or
calpain cleavage are found in human HD postmortem brain
(DiFiglia et al. 1997; Lunkes et al. 2002) or in mouse
models of HD (Li et al. 2000; Schilling et al. 2007). At
least two smaller N-terminal fragments, called cp-A and
cp-B, have been described (Kim et al. 2006; Lunkes et al.
2002). Deletion of aa 104–114 prevented release of cp-A
and the production of the longer cp-B cleavage product was
reduced after deletion of aa 205–214. The release of cp-A
and cp-B can be inhibited by pepstatin, suggesting that
the protease(s) responsible for the generation of the htt
N-terminal cp-A and cp-B belong to the family of aspartyl
endopeptidases. In addition, short N-terminal fragments
(Cp-1 and Cp-2) can be released by caspase independent
proteolytic cleavage of htt in a PC12 cell model expressing
full-length mhtt (Ratovitski et al. 2007). Recent studies
identiﬁed the length of two short htt N-terminal cleavage
products. In the HdhQ150 knock-in mouse model htt exon 1
was identiﬁed as the smallest cleavage product with a length
of 90 aa (Landles et al. 2010) and in vitro studies suggest htt
cleavage at position 167 (generating the fragment cp-2)
(Ratovitski et al. 2009).
The proteolytic pathways that generate short htt N-ter-
minal cleaved fragments are still poorly understood. A
better understanding of htt proteolytic processing provides
important insights in the early mechanisms of HD patho-
genesis and will lead to the development of new HD
therapeutics. Our previous work showed that in the HD
N171-18Q, -44Q, and -82Q mouse model, cleavage of htt
appears to be a normal process (Schilling et al. 1999). We
have recently detected an N-terminal fragment of mhtt in
the HD N171-82Q mouse model and in human HD post-
mortem brain lacking the epitope 115–129 (Schilling et al.
2007) and being similar to cp-A detected in NG108-15
cells expressing mhtt (Lunkes et al. 2002).
Using an in vitro cell culture model, we have now
identiﬁed a region between aa 116–125 in htt where the
efﬁciency of N-terminal cleavage is strongly affected by
mutations with the cleavage either being suppressed or
enhanced. The mutation D121–122 that enhances cleavage,
and hence mhtt N-terminal fragment release results in
increased aggregation, apoptotic processes and in a
decrease of neuronal cell viability. Our data show that the
N-terminal cleavage of mhtt can be modulated with an
effect on aggregation and cell death rate.
Materials and Methods
Vector Construction
Expression constructs containing htt cDNA encoding the
ﬁrst 171 (N171) and 233 (N233) amino acids with 18
glutamines (wild-type htt) or 82 glutamines (mhtt) were
cloned into pcDNA3.1 or pRC/CMV, whereas the num-
bering of amino acids is based on wild-type htt sequence
with 23 repeats. Addition of the myc-epitope tag at the
C-terminus of htt-N171-18Q and generation of shorter
htt constructs by introduction of translational termination
codon into htt-N171-18Q at aa 116 or 121 were performed
by PCR ampliﬁcation. The 50 primer for producing
htt-N171-18Q-myc incorporated a c-myc epitope and an
EcoRI site in its 50 end. In the 30 end of the 30 primer, an
XbaI site was incorporated. The primers for generating stop
codons in htt-N171-18Q included BamHI restriction sites.
PCR products were digested and subcloned into similarly
digested pcDNA3.1. Site-directed mutagenesis was per-
formed by using the QuikChange II kit (Stratagene),
according to manufacturer’s protocol. All htt expression
constructs and CAG repeat lengths were conﬁrmed by
DNA sequencing.
Cell Culture and Transfection
HEK 293 (human embryonic kidney) cells, HeLa (human
cervical carcinoma) cells, COS-7 (monkey kidney) cells
and N2a (mouse neuroblastoma) cells were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) with high
glucose, stable glutamine and supplemented with 10% fetal
calf serum (FCS) and 1% penicillin/streptomycin at 37C
with 5% CO2.S T Hdh
?/Hdh
? cells (mouse striatal pre-
cursors) were grown at 33C in DMEM with 10% FCS and
a selection by G418 for selection (Trettel et al. 2000). All
cell culture reagents were obtained from PAA laboratories,
Austria. Cells were transiently transfected with htt con-
structs using Lipofectamine
TM 2000 (Invitrogen). Cells
were seeded 24 h before transfection in six-well plates and
incubated with a mixture of 6 lg DNA and 12 ll
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TM 2000 for 48 h. Cell viability of N2a cells
was assessed 48 h after transfection by trypan blue dye
solution (Sigma). Transfected N2a cells were resuspended
in culture medium containing 0.1% trypan blue dye solu-
tion and examined by light microscopy. Viable and non-
viable cells were then counted, and the score obtained
expressed vital cells in percent of total cells.
Antibodies
The polyclonal antibody N18 (sc-8767), the monoclonal
antibody c-myc 9E10 (sc-40) and the b-actin monoclonal
antibody (sc-47778) were purchased from Santa Cruz
Biotechnology. The b-tubulin monoclonal antibody
(GTX11307) is from GeneTex and the cytochrome c
monoclonal antibody (7H8.2C12) is from BioVision. Dif-
ferent antibodies were used to detect various regions of the
htt protein, whereas the monoclonal antibodies 1C2
(MAB1574) and anti-huntingtin 115-129 (MAB5490) were
purchased from Chemicon International. Peptide-speciﬁc
antibodies designated htt 55–66 and htt 81–90 were
described previously (Schilling et al. 2007). Peptide
sequences are numbered on wild-type human htt with 23Q
(GenBank Accession Number NM_002111).
Immunoblot Analysis
Transfected cells were harvested in PBS, centrifuged and
cell pellets were resuspended in lysis buffer (50 mM Tris–
HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton
X-100 and a cocktail of protease inhibitors), followed by
soniﬁcation. The whole cell protein concentration was
determined by using the bradford method (Biorad). Lysates
were resolved by SDS-PAGE on 10 and 15% Tris–HCl
acrylamide gels. Proteins were transferred to nitrocellulose
membranes, blocked with 5% milk powder in PBS and
incubated with different primary antibodies (see above)
overnight at 4C. Immunoblots were developed with per-
oxidase-conjugated secondary antibodies (Pierce) and
detected by using ECL western blotting substrate (Pierce).
Immunoﬂuorescence
COS-7 and N2a cells were grown on glass coverslips and
transiently transfected with mhtt constructs as described
above. 48 h after transfection, cells were washed with PBS
and ﬁxed for 20 min at -20C in methanol. Cells were
blocked with 1% BSA and 2% FCS in PBS for 20 min at
room temperature after three times of washing with PBS.
Primary antibodies were diluted (1:1500 for htt 81–90 and
1:200 for htt 115–129) in blocking buffer and slides were
incubated with the primary antibody for 45 min at room
temperature and then washed with PBS. Secondary
antibodiesconjugatedtoAlexaFluor488orAlexaFluor594
were added at a 1:300–1:400 dilution for 45 min at room
temperature. Cells were washed three times with PBS,
counterstained with DAPI (40,6-diamidino-2-phenylindole,
Sigma) and mounted onto slides. Immunoﬂuorescence was
observed using a Zeiss Axiovert 200 Apotome and images
were colourized and merged using the Adobe-Photoshop
software. Aggregate formation was manually counted by
examining 200 cells per coverslip after transfection.
Aggregates were deﬁned as a clearly encompassed region of
densehttstaining.Cellscontainingseveralaggregatesofany
size were considered to have one aggregate.
Cleavage Product Quantitation
Both blotting and imaging with the Odyssey infrared
imaging system (LI-COR) were performed according to
manufacturer’s instruction. The HEK 293 cell lysates were
fractionated on 10% SDS-PAGE-gels, transferred to
nitrocellulose membranes and probed with the primary
antibody htt 55–66. For detection, anti-rabbit Alexa Fluor
680 antibody (Invitrogen) was added.
Filter Retardation Assay
For the ﬁlter retardation assay protein extracts were diluted
with 2% SDS and 8% b-mercaptoethanol in PBS, heated at
100C for 5 min and ﬁltered through a cellulose acetate
membrane (0.2 lm pore size, Schleicher & Schuell) using
a MiniFold-1 Dot-Blot System (Whatman) after equaliza-
tion concerning the main protein product by protein
quantitation. Membrane was washed with water and sub-
jected to the general procedure of immunoblot analysis by
using an anti-htt antibody as described above.
Apoptosis Assays
Apoptosis was assessed 48 h after transfection of HEK 293
cells by analysis of caspase 3 and caspase 7 activities using
the Caspase-Glo
TM 3/7 assay kit (Promega) according to
manufacturer’s protocol. After incubation at room temper-
ature for 3 h, luminescence was measured using a Mithras
LB 940 Multilabel Reader (Berthold Technologies). Each
sample was measured in triplicate and blank values were
substracted. Cytochrome c release into the cytosol was
assessed 48 h after transfection of HEK 293 cells. Mito-
chondrialandcytoplasmicfractionswereseparatedusingthe
Cytochrome c Releasing Apoptosis Assay Kit (BioVision).
Statistical Analysis
All values were obtained from at least three independent
repeated experiments and expressed as mean ± SD.
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P\0.05 was considered statistically signiﬁcant.
Results
N-Terminal Proteolysis of Htt in Cell Culture
To analyze the N-terminal proteolytic processing of human
htt, we transiently transfected HEK 293 cells with
expression plasmids encoding the ﬁrst N-terminal 171 and
233 aa with 18 or 82 glutamines (see Fig. 1a for scheme of
used constructs). Immunoblot analysis of whole cell
extracts using the antibody htt 81–90 (Schilling et al. 2007)
revealed expression of htt-N171-18Q and htt-N233-18Q. In
addition to the uncleaved htt-N171-18Q and htt-N233-18Q
proteins, smaller htt fragments with equal size were
detected in both lanes (Fig. 1b, arrow). To examine if these
smaller fragments were generated independently of polyQ
length, we compared the expression from htt-N171-82Q
and htt-N233-82Q constructs in HEK 293 cells. In both
cases, a smaller fragment could be observed in addition to
the uncleaved htt protein product on immunoblot using the
antibody htt 81–90 (Fig. 1c, arrow). Interestingly, the
cleavage of htt-N233-82Q seems to be much more efﬁcient
compared to htt-N171-82Q. To test if the observed smaller
htt fragment is an N-terminal cleavage product, we trans-
fected HEK 293 cells with the construct htt-N171-18Q-
myc containing a myc-tag at the C-terminus and analyzed
cell lysates by SDS-PAGE and immunoblotting. The anti-
body htt 81–90 detected the truncated htt-N171-18Q-myc
protein at the expected size of around 30 kDa and the
approximately 10 kDa smaller cleavage product (Fig. 1d).
In contrast, the anti-c-myc antibody detected the uncleaved
htt protein product only, indicating that the lower protein
band represents an N-terminal cleavage product. To
exclude the possibility that N-terminal htt proteolytic
processing is speciﬁc for HEK 293 cells, we investigated
if the identical fragment was also observed in other
non-neuronal and neuronal cell lines. Transfection of HEK
293, HeLa, COS-7, STHdh
?/Hdh
? and N2a cells with
htt-N233-82Q followed by immunostaining with the anti-
bodies 1C2 and htt 81–90 showed a similar N-terminal
cleavagefragment(arrows)inalltestedcelllines(Fig. 1e,f).
These data suggest that cleavage occurs at a speciﬁc region
within htt and identical proteases may act to generate
the N-terminal fragment of similar size in different cell
types.
Distinct Nuclear and Cytoplasmatic Aggregate
Formation in Cells Expressing Mhtt
To analyze the subcellular localization of htt-N233-82Q
and its N-terminal fragment, double immunoﬂuorescence
studies were performed 48 h after transfection of COS-7
cells with htt-N233-82Q expression plasmids. Using anti-
bodies selectively detecting N-terminal htt epitopes at aa
81–90 and aa 115–129, immunoﬂuorescence studies
Fig. 1 N-terminal proteolytic cleavage of htt in non-neuronal and
neuronal cells. a Schematic diagrams of htt constructs used.
b Expression of htt-N171-18Q and htt-N233-18Q in HEK 293 cells.
Immunoblot was probed with the antibody htt 81–90 and cleavage
products are indicated by an arrow. c Immunoblot of transfected HEK
293 cells expressing htt-N171-82Q and htt-N233-82Q using the
antibody htt 81–90. mhtt cleavage fragments with 82Q were detected
(arrow). d HEK 293 cells were transfected with the construct htt-
N171-18Q-myc (C-terminal myc-epitope tag). The anti-c-myc
antibody was able to detect the main htt protein band and not the
N-terminal fragment. As control htt-N171-18Q-myc extract was
probed with the antibody htt 81-90 for detection of the smaller
N-terminal cleavage product. e, f mhtt processing in various cell lines.
Immunoblots of protein extracts from nontransfected (-) and htt-
N233-82Q-transfected (?) HEK 293, HeLa, COS-7, STHdh
?/Hdh
?,
and N2a cells. After 48 h, cells were lysed and analyzed by
immunoblot with the antibodies e 1C2 and f htt 81–90. A similar
mhtt N-terminal fragment was detected in all cell lines (arrows)
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123revealed cytoplasmic and nuclear inclusions containing
aggregated mhtt (Fig. 2a, row 1–4). Htt-N233-82Q-derived
aggregates detected with both htt N-terminal antibodies
resulted in co-localized staining in the perinuclear region
(Fig. 2a, row 1) and in the nucleus (Fig. 2a, row 2,
arrowhead). In addition, staining with both htt N-terminal
antibodies demonstrated mhtt perinuclear and nuclear
inclusions only detected by the antibody htt 81–90 lacking
the epitope aa 115–129 (Fig. 2a, row 3–4, arrow). Counting
of inclusions detected by the antibodies htt 81–90 and htt
115–129 revealed that 77% of htt aggregates are perinu-
clear and 15% nuclear localized (Fig. 2b). A few inclusions
detected by the antibody htt 81–90 and not by the antibody
htt 115–129 are localized in the perinuclear region (5%) or
in the nucleus (3%).
Hence, both uncleaved htt-N233-82Q protein and the
N-terminal cleavage fragment seem to form aggregates in
the perinuclear region and in the nucleus.
Analysis of the Htt N-Terminal Fragment Indicates
Cleavage Around aa 120
To map the region in htt where cleavage takes place, HEK
293 cells were transfected with htt-N233-82Q and analyzed
for mhtt expression with antibodies recognizing different
N-terminal htt epitopes (depicted in Fig. 3a). On immu-
noblots the N-terminal antibodies N18, 1C2, htt 55–66 and
htt 81–90 detected both the uncleaved htt protein product
and the smaller htt cleavage fragment (Fig. 3a, arrow). By
contrast, the htt antibody against epitope 115–129 did not
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Fig. 2 N-terminal mhtt
aggregates in COS-7 cells.
a Transiently transfected COS-7
cells expressing htt-N233-82Q
exhibit perinuclear (row 1) and
nuclear (row 2, arrowhead)
inclusions stained with the
N-terminal antibodies htt 81–90
and htt 115–129 or with the
antibody htt 81–90 only (row
3–4, arrow). Scale bars are
20 lm. b Distribution of mhtt
aggregates in COS-7 cells
expressing htt-N233-82Q.
Transfected cells with
aggregates stained by the
antibodies htt 81–90 and htt
115–129 or htt 81–90 alone
were counted per coverslip in
independent experiments
(n = 3)
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123recognize the lower protein band, suggesting this epitope is
either C-terminal to the cleavage site or destroyed by
cleavage. These data suggest that proteolytic processing
occurs between aa 90 and 129. Indeed, introduction of stop
codons into htt-N171-18Q at aa 116 and 121 revealed a
similar mobility of htt-N120-18Q on SDS-PAGE compared
to the mobility of the N-terminal cleavage fragment
derived from htt-N171-18Q (Fig. 3b). Furthermore, the
N-terminal cleavage fragment detected in the mouse brain
homogenate of HD N171-82Q line 81 transgenic mice
(Schilling et al. 1999), the N-terminal cleavage fragment of
htt-N233-82Q in HEK 293 cells and the protein htt-N120-
82Q expressed in HEK 293 cells are all in the same
molecular range on SDS-PAGE (Fig. 3c, arrow). The mhtt
transgenic protein product expressed in HD N171-82Q line
81 was not detectable, probably due to the inability of htt
81–90 to recognize the uncleaved htt protein. It is notably
that this particular transgenic protein product can be
detected by the 1C2 antibody (Schilling et al. 1999).
Expression of full-length mhtt after transfection of
HEK 293 cells with htt-FL-82Q revealed on SDS-PAGE
an N-terminal cleavage fragment that was running in the
same molecular range like the N-terminal cleavage frag-
ment derived from HD N171-82Q line 81 mice (Fig. 3d,
arrow). However, a second protein band in addition to the
N-terminal cleavage fragment could be detected after
expression of htt-FL-82Q with the size predicted for cp-B
but the signal was low. Our data suggest that proteolytic
cleavage is polyglutamine length-independent and occurs
around aa 120 in vitro and in vivo releasing an N-terminal
fragment lacking the epitope 115–129.
Efﬁciency of Cleavage is Strongly Affected
by Mutations within the Putative Cleavage Region
To analyze the N-terminal cleavage region in htt more
precisely, HEK 293 cells were transfected with htt-N171-
18Q constructs containing sequential deletions of two aa in
Fig. 3 Mapping of htt
N-terminal cleavage.
a Antibody mapping of mhtt
proteolytic cleavage in htt-
N233-82Q-transfected cells (?)
and as control nontransfected
cells (-). 48 h after
transfection, cell lysates were
analyzed by immunoblot with
the N-terminal htt antibodies
N18, 1C2, htt 55–66, htt 81–90,
and htt 115–129. All antibodies,
except htt 115–129, recognized
the mhtt cleavage product
(arrow) running approximately
10 kDa lower on SDS-PAGE
than the main mhtt protein
product. b The N-terminal
fragment of htt-N171-18Q
(approximately 18 kDa)
migrates on SDS-PAGE in the
same molecular range as the
protein htt-N120-18Q detected
on immunoblot with the
antibody htt 81–90. c The
protein htt-N120-82Q, the
N-terminal cleavage fragment
of htt-N233-82Q (arrow) and
d of htt-FL-82Q from
transfected HEK 293 cells
have the same mobility on
SDS-PAGE compared to the
mhtt cleavage fragment from
brain homogenate of HD
N171-82Q line 81 transgenic
(tg) mouse (lowest arrow)
shown on immunoblot with the
antibody htt 81–90
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123the region aa 120–130 (Fig. 4a, framed) and htt-N171-18Q
constructs with two larger deletions D93–116 and
D116–125, respectively. All double aa deletion mutants
generated smaller N-terminal fragments (Fig. 4b, arrow) as
was detected by immunostaining with the antibody htt
81–90,however,withvariationinstainingintensitybetween
individual experiments and the different mutants. Notably,
the mutation D121–122 consistently resulted in enhanced
efﬁciencyofcleavageinallrepeatedexperiments.Thelarger
deletion D93–116 had no effect on cleavage fragment for-
mationcomparedtothedeletionD116–125,whichshoweda
strong reduction in fragment release. In addition, we ana-
lyzed htt fragment release from htt-N171-18Q mutants with
sequential double substitutions into alanine in the region aa
120–130 (Fig. 4c, arrow). Here, we could identify the
mutation AA124–125 with the strongest and sustained
reduction in fragment release in all repeated experiments.
For further analyses, the mutations AA124–125,
D116–125, and D121–122 resulting in either strong
reduced or enhanced N-terminal cleavage were used in the
htt-N233-82Q background due to the fact that this protein
gets more efﬁciently cleaved than htt-N171-82Q (Fig. 1c).
The mutations AA124–125 and D116–125 also affected
cleavage when introduced into the construct htt-N233-82Q,
containing a polyQ repeat in the pathological range, with
reduction of fragment formation of 3.2 ± 0.3-fold and
2.8 ± 0.4-fold (n = 3), respectively (Fig. 4d, arrow).
Similarly to the mutant htt-N171–18Q D121–122 the
mutation D121–122 in htt-N233-82Q results in a
2.5 ± 0.1-fold (n = 3) enhanced cleavage as revealed by
quantitation of immunoblots. Interestingly, the mutation
D105–114, previously shown to inhibit release of cp-A in
NG108-15 cells (Lunkes et al. 2002), did not affect the
generation of cleaved N-terminal fragment in our trans-
fected HEK 293 cell model and in stable PC12 cells
expressing full-length mhtt (Ratovitski et al. 2007). How-
ever, in NG108-15 cells cp-A was only detectable in the
present of proteasome inhibitors (Lunkes et al. 2002),
whereas in our cells transfected with truncated htt con-
structs the N-terminal fragment could be detected without
proteasome inhibition.
We conclude that the htt N-terminal region between aa
116–125 is important for cleavage in transfected HEK 293
cells. Mutations within the putative cleavage region seem
to differentially affect htt cleavage efﬁciency independent
of polyglutamine length, resulting in either a strong
reduction (AA124–125) or an increase (D121–122) of
cleaved fragment release.
Deletion of aa 121–122 in Mhtt Results in Activation
of Apoptotic Processes, Decreased Neuronal Cell
Viability and Increased Aggregation
To study the cellular effect of mutations in the putative
mhtt cleavage region, we transfected HEK 293 cells with
htt-N233-82Q and its mutants to monitor execution of
apoptotic pathways by measuring caspase 3 and caspase 7
activities using a luciferase assay (Fig. 5a). In cells
expressing the mutant htt-N233-82Q D121–122, which
produce higher amounts of N-terminal fragment, the
Fig. 4 Mutations within the N-terminal cleavage region of htt.
a Sequence of the ﬁrst 171 aa of htt is shown with the region of
interest where double aa deletions or double alanine substitutions
were inserted between aa 120–130 (framed). Htt-N171-18Q with
b sequential two aa deletions, D93–116, D116–125 and c sequential
substitutions with two alanines were expressed in HEK 293 cells and
detected on immunoblot with the antibody htt 81–90. The N-terminal
cleavage fragment is indicated by an arrow. D121–122 consistently
increased cleavage fragment release, whereas D116–125 and
AA124–125 showed a strong reduction in formation of cleavage
fragment. d Mutations D121–122, AA124–125, D116–125, and
D105–114 were constructed in the htt-N233-82Q background,
transfected in HEK 293 cells, and detected by immunostaining with
the antibody 1C2. The N-terminal cleavage fragment is approximately
38 kDa (arrow)
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123caspase 3 and caspase 7 activities were signiﬁcantly higher
compared to cells expressing htt-N233-82Q (1.98 ± 0.16-
fold, n = 3, *** P\0.001). There was no statistically
signiﬁcant difference in caspase activity in cells transfected
with vector control, htt-N233-82Q or its mutant htt-N233-
82Q AA124–125 with reduced efﬁciency of cleavage.
Therefore, we could not determine in this cellular model
whether a strong reduction in cleavage fragment release by
the mutation AA124-125 results in decreased effector
caspase activities. Hence, expression of htt-N233-82Q does
not activate apoptotic processes, whereas expression of the
mutant htt-N233-82Q D121–122 results in an increased
accumulation of N-terminal cleavage fragments and in
enhanced caspase 3 and caspase 7 activities which is an
advanced event in apoptotic and programmed cell death.
Figure 5b shows an immunoblot using the antibody 1C2
detecting htt-N233-82Q and its mutants htt-N233-82Q
AA124-125 and htt-N233-82Q D121–122 with either
reduced or increased release of the N-terminal fragment
used for luciferase assay. Next, we used a complementary
approach to conﬁrm activation of apoptotic processes by
detecting the amount of cytochrome c released from mito-
chondria into the cytosol due to the mutant htt-N233-82Q
D121–122. Release of cytochrome c from mitochondria is
one of the major initial steps in induction of apoptosis. As
shown in Fig. 5c, expression of the mutant htt-N233-82Q
D121–122 increased the cytochrome c content in the cyto-
solic fraction. Quantiﬁcation of cytochrome c in the cyto-
solic fraction of cells expressing the mutant htt-N233-82Q
D121–122 revealed that the amount of cytochrome c was
2.4 ± 0.7-fold (n = 3) higher compared to cells expressing
htt-N233-82Q.
Furthermore, we analyzed the viability of neuronal cells
transfected with htt-N233-82Q and its mutant htt-N233-
82Q D121–122 (Fig. 6a). In N2a cells, expressing the
mutant htt-N233-82Q D121–122, cell viability was 16.5%
Fig. 5 Caspase 3 and caspase 7 activities in HEK 293 cells
expressing mhtt. a Caspase 3 and caspase 7 activities of transfected
HEK 293 cells expressing htt-N233-82Q and its mutants. Transfection
of the empty vector pRC/CMV served as control. Increased activities
of caspase 3 and caspase 7 are demonstrated in increased relative light
units (RLU). Luminescence data were obtained 48 h after transfec-
tion. The difference in caspase 3 and caspase 7 activities of cells
transfected with htt-N233-82Q D121–122 was statistically signiﬁcant
compared to htt-N233-82Q (n = 3, *** P\0.001). b Immunoblot
with the antibody 1C2 shows the expression levels of transfected mhtt
constructs used for luciferase assay. c Immunoblot showing the
increased level of cytochrome c in the cytosolic fraction of htt-N233-
82Q D121–122 transfected HEK 293 cells. The blots were probed
with the antibody anti-cytochrome c and the anti-ß-tubulin antibody
Fig. 6 Cell viability of transfected N2a cells expressing mhtt. a Cell
viability of N2a cells expressing htt-N233-82Q and its mutant htt-
N233-82Q D121–122. Transfection of the empty vector pRC/CMV
served as control. Cell viability was assessed 48 h after transfection
using trypan blue dye solution. In cells expressing the mutant htt-
N233-82Q D121–122 cell viability was 16.5 % (n = 3, ** P\0.01)
reduced compared to cells expressing htt-N233-82Q. b Aggregate
formation in N2a cells expressing either htt-N233-82Q or its mutant
htt-N233-82Q D121–122. Aggregates of mhtt are labeled with the
antibody htt 81–90
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(n = 3, ** P\0.01). There was no statistically signiﬁcant
difference in N2a cell viability between vector control and
htt-N233-82Q suggesting that expression of the ﬁrst 233 aa
and appearance of the corresponding N-terminal cleavage
product are not toxic. However, N2a cells expressing either
htt-N233-82Q or the mutant htt-N233-82Q D121–122
exhibit well-deﬁned inclusion bodies (Fig. 6b).
To study the efﬁciency of mhtt aggregation, we per-
formed indirect immunoﬂuorescence in transfected COS-7
cells showing intracellular inclusion bodies 48 h after
transfection with htt-N233-82Q and its mutants. Quantita-
tion revealed that approximately 18% (n = 6) of cells
transfected with htt-N233-82Q contained at least one
microscopic visible aggregate stained with the antibody htt
81–90 (Fig. 7a). In cells expressing the construct htt-N233-
82Q AA124–125, with decreased N-terminal cleavage
fragment release, aggregate formation was signiﬁcantly
reduced to 10% (n = 6, *P\0.05). In contrast to
htt-N233-82Q, aggregate frequency was about 2.5-fold
higher (45%, n = 6, *** P\0.0001) in cells expressing
htt-N233-82Q D121–122, a mutant with enhanced cleavage
of 2.5-fold. In addition, we used ﬁlter retardation assay
with lysates of cells transfected with htt-N233-82Q and
indicated mutants (Fig. 7b). As expected, the spot from the
mutant htt-N233-82Q D121–122 showed the highest den-
sity. The mutants htt-N233-82Q AA124–125 and htt-N233-
82Q D116–125 did not show a visible reduced density
when compared to htt-N233-82Q but this is probably due
to a overall low retardation of aggregates from cell lysates.
In conclusion, our data suggest that expression of
htt-N233-82Qisnottoxicincellculture.However,themuta-
tionD121–122withintheputativecleavageregionenhanced
N-terminal cleavage and subsequently aggregation of mhtt
N-terminal fragments. Moreover, activation of apoptotic
processes and decreased cell viability is associated with this
mutation.
N-Terminal Mhtt with Speciﬁc Protein Length Induces
Cell Death
We have shown that the expression of htt-N233-82Q in cell
culture does not induce apoptotic processes or reduces
neuronal cell viability. To analyze if other short htt
N-terminal proteins with identical polyglutamine stretches
but different protein lengths induce apoptotic processes and
cell death, we expressed mhtt with the ﬁrst 120, 171, and
233 aa in HEK 293 cells to measure effector caspase
activity (Fig. 8a). In cells expressing htt-N171-82Q the
caspase 3 and caspase 7 activities were signiﬁcantly higher
compared to cells expressing the shorter protein htt-N120-
82Q (2.65 ± 0.56-fold, n = 3, **P\0.01). There was no
statistically signiﬁcant difference in caspase activity in
cells transfected with htt-N120-82Q or htt-N233-82Q
compared to the vector control. Expression of the proteins
htt-N120-82Q, htt-N171-82Q, and htt-N233-82Q was
detected with the antibody N18 (Fig. 8b).
Furthermore, the neuronal cell viability was determined
after transfection of N2a cells with these short mhtt con-
structs (Fig. 8c). Cells expressing htt-N171-82Q showed a
reduction of 14.5% (n = 3, *P\0.05) in cell viability
compared to cells expressing htt-N120-82Q. There was no
statistically signiﬁcant difference in N2a cell viability
between vector control and htt-N120-82Q or htt-N233-82Q
suggesting that expression of mhtt with 171 aa is toxic.
However, N2a cells expressing either htt-N120-82Q,
htt-N171-82Q or htt-N233-82Q exhibit well-deﬁned
inclusion bodies (Figs. 6b, 8d). Quantitation of aggregates
Fig. 7 Aggregation of mhtt fragments. a Quantitation of aggregates
in COS-7 cells expressing the indicated mhtt constructs. 200 trans-
fected cells were counted per coverslip in independent experiments
(n = 6, * P\0.05; *** P\0.0001). b Aggregate formation was
detected by ﬁlter retardation assay. Captured protein aggregates from
transfected HEK 293 cell lysates were shown using the antibody htt
81–90. An increase of aggregation was observed in cells expressing
the mutant htt N233-82Q D121–122. Non-transfection of HEK 293
cells served as a control
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htt-N233-82Q, and the mutant htt-N233-82Q D121–122
revealed that only the mutant htt-N233-82Q D121–122
shows a signiﬁcant increase in aggregate formation com-
pared to the vector control (Fig. 8e).
To determine if the AA124-125 substitution in
htt-N171-82Q (causing a reduction in fragment release) has
an effect on neuronal cell viability, we expressed htt-N171-
82Q and its mutant htt-N171-82Q AA124-125 in N2a cells
(Fig. 8f). There was no statistically signiﬁcant difference in
cell viability between htt-N171-82Q and htt-N171-82Q
AA124-125 indicating that expression of mhtt with 171 aa
is toxic on its own and a reduction of cleavage fragment
without an effect.
These data suggest that the intracellular generation of a
speciﬁc N-terminal cleavage fragment with a length of
approximately 120 aa is not toxic in cell culture. The
htt-N171-82Q protein, previously observed to be toxic in a
transgenic mouse model (Schilling et al. 1999), had an
effect on neuronal cell viability compared to the proteins
htt-N233-82Q and htt-N120-82Q. The toxicity mediated by
htt-N171-82Q is not due to an increase in aggregation,
since the number of aggregates after expression of mhtt
with the ﬁrst 120, 171, and 233 aa is equal. Thus, our data
suggest that mhtt N-terminal fragments of speciﬁc size may
contribute to mhtt-induced cell death.
Discussion
Numerous studies provide evidence that speciﬁc mhtt
N-terminal fragments are toxic to neurons and are sufﬁ-
cient to cause HD (Davies et al. 1997; Graham et al. 2006;
Ratovitski et al. 2009; Schilling et al. 1999; Wellington
Fig. 8 mhtt of speciﬁc size increases apoptotic processes and
decreases neuronal cell viability. a Caspase 3 and caspase 7 activities
of transfected HEK 293 cells expressing htt-N120-82Q, htt-N171-
82Q, and htt-N233-82Q. Transfection of the empty vector pRC/CMV
served as control. Increased activities of caspase 3 and caspase 7 are
demonstrated in increased relative light units (RLU). Luminescence
data were obtained 48 h after transfection. The difference in caspase 3
and caspase 7 activities of cells transfected with htt-N171-82Q was
statistically signiﬁcant compared to htt-N120-82Q (n = 3,
** P\0.01). b Immunoblot with the antibody N18 reveals the
expression levels of transfected mhtt constructs in HEK 293 cells.
c Cell viability of N2a cells expressing either htt-N120-82Q, htt-
N171-82Q or htt-N233-82Q. Transfection of the empty vector pRC/
CMV served as control. Cell viability was assessed 48 h after
transfection using trypan blue dye solution. In cells expressing
htt-N171-82Q cell viability was 14.5% (n = 3, * P\0.05) reduced
compared to cells expressing htt-N233-82Q. d Aggregate formation
in N2a cells expressing either htt-N120-82Q or htt-N171-82Q.
Aggregates of mhtt are labeled with the antibody htt 81–90.
e Quantitation of cells containing aggregates stained with the
antibody htt 81–90 after expression of the indicated mhtt constructs.
200 transfected cells were counted per coverslip (n = 3,
*** P\0.001). f Cell viability of N2a cells expressing either htt-
N171-82Q or its mutant htt-N171-82Q AA124-125. Transfection of
the empty vector pRC/CMV served as control (n = 3, * p\0.05)
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length have been described in human HD postmortem
brain, in mouse models of HD and cell culture systems
(DiFiglia et al. 1997; Gafni and Ellerby 2002; Li et al.
2000; Lunkes et al. 2002; Mende-Mueller et al. 2001;
Wellington et al. 2000). To further analyze htt proteolytic
processing, we developed a cell culture model using tran-
sient transfection with DNA expression plasmids encoding
the ﬁrst 171 or 233 aa of htt containing stretches of either
18 or 82 glutamines. In addition to the expressed main htt
protein product an approximately 10 kDa smaller htt
fragment lacking the epitope aa 115–129 was detected
irrespective of htt protein size and length of polyQ by
immunoblot analysis. In comparison, the cleaved N-ter-
minal fragment that was identiﬁed in the transgenic mouse
model of HD expressing htt-N171-82Q is running at the
same molecular size on SDS-PAGE as htt-N120-82Q and
the cleavage fragment from htt-N233-82Q expressed in
HEK 293 cells suggesting that cleavage in vitro and in vivo
is around aa 120. Furthermore, this N-terminal cleavage
band was detected on immunoblot after expression of htt-
N233-82Q in non-neuronal and neuronal cell lines. It is
likely that identical proteases act in the various cell lines.
We cannot rule out that this particular cleavage band
consists of several similar sized fragments, which are not
separable on SDS-PAGE or that the cleavage event varies
in different cell types by only one or a few amino acids.
The size of the mhtt N-terminal fragment described in
this study is much smaller than the fragments generated by
caspases or calpains (Gafni et al. 2004; Graham et al. 2006;
Wellington et al. 2000). YAC128 mice expressing full-
length mhtt that has become resistant to caspase 6 cleavage
by mutation of aa 586 are protected against behavioural
and neuropathological features of HD (Graham et al.
2006). This suggests that caspase 6 cleavage of mhtt is a
critical initial cleavage following further fragmentation of
mhtt and development of HD in mice. However, in a dif-
ferent study caspase inhibitors did not prevent further
cleavage into smaller N-terminal fragments in a PC12 cell
culture model (Ratovitski et al. 2007). In this study, we
could demonstrate generation of short N-terminal frag-
ments after expression of truncated htt proteins with either
171 or 233 aa independent of previous caspase cleavage.
The fragment identiﬁed in this study is comparable in
size to the cp-A cleavage product found in the nucleus and
generated by cleavage between epitope 1–82 and epitope
115–129 in NG108-15 cells expressing full-length mhtt
with 116Q (Lunkes et al. 2002). In addition, the fragment is
of comparable size to the fragment detected in mice
expressing full-length mhtt with 148Q taking the different
polyQ lengths into account (Tanaka et al. 2006). Lunkes
et al. detected a second htt fragment, termed cp-B, which
was found to be predominantly in the cytoplasm and can be
released by cleavage between aa 115–129 and aa 214–229.
In our cell culture model expressing truncated htt questions
concerning the cp-B fragment cannot be addressed since
only one fragment of similar size as cp-A is detectable.
Hence, our cell model expressing truncated htt is a good
opportunity to analyze the effect of one speciﬁc N-terminal
cleavage fragment only without the potential obscuring
effect of additional fragments. Indirect immunoﬂuores-
cence studies with transfected cells expressing htt-N233-
82Q showed that the N-terminal cleavage product, which is
detectable with the antibody htt 81–90 but not with the
antibody htt 115–129, is located in the perinuclear region
and the nucleus. It cannot be excluded that both uncleaved
htt-N233-82Q protein and the N-terminal cleavage frag-
ment form mixed aggregates in the perinuclear and nuclear
region detectable with the antibodies htt 81–90 and htt
115–129. These ﬁndings are consistent with our previous
data demonstrating N-terminal proteolytic cleavage
between aa 81–90 and aa 115–129 generating N-terminal
fragments accumulating in the nuclei of neurons in the
cortex of human HD postmortem brain and in the tissue of
HD N171-82Q mouse brain (Schilling et al. 2007). Others
have also shown that not only small N-terminal fragments,
such as cp-A, but also larger caspase-derived N-terminal
htt fragments enter the nucleus (Sawa et al. 2005; Warby
et al. 2008a). Neurotoxicity may reﬂect nuclear transloca-
tion and aberrant protein interactions of mhtt N-terminal
fragments with interactors such as Sp1 (Dunah et al. 2002),
p53, and CREB binding protein (CBP) (Nucifora et al.
2001; Steffan et al. 2000).
Our mutagenesis studies demonstrated that the region aa
116–125 is important for cleavage efﬁciency. We discov-
ered different mutations that caused either strongly
enhanced or reduced cleavage. On the other hand, a deﬁnite
cleavage site could not be located this way and it is not
clear whether the involved protease(s) only recognize the
substrate htt between aa 116–125 or even cleave within this
speciﬁc region. Furthermore, it is possible that a protease
cleaves within this region and acts on more than one site as
reported for the c-secretase in Alzheimer’s disease (Matt-
son 2004) or that the region is accessible for more than one
protease. Sequence-based structural predictions suggest
that full-length htt contains four HEAT domains and four
proteolytic susceptible PEST domains (Andrade and Bork
1995; Rechsteiner and Rogers 1996; Takano and Gusella
2002). PEST domain 2 with cleavage sites for caspases and
calpains is well characterized. However, the region
between aa 116–125 is located in the predicted PEST
domain 1 and thus most likely accessible for proteases.
The mutations D116–125, AA124–125, and D121–122
within the putative cleavage region affect the cleavage
efﬁciency with either reduced or increased fragment
release. There was no internal mutation totally preventing
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may result in cleavage at alternative sites. Moreover,
cleavage efﬁciency might be mediated by post-translational
modiﬁcation as was previously shown by phosphorylation
of S421 causing reduced htt cleavage by caspase 6 (Warby
et al. 2008b). We cannot exclude that mutations within the
putative cleavage region may alter the post-translational
modiﬁcation of htt protein resulting in modulation of
cleavage efﬁciency or protein stability of N-terminal
fragments.
Our analysis of cells expressing htt-N233-82Q and its
mutants revealed that expression of htt-N233-82Q alone
does not exhibit any toxicity measured by caspase 3 and
caspase 7 activities, cytochrome c release and neuronal cell
death rate. Therefore, a reduction in cleavage fragment
release by the mutation AA124–125 has thus no effect,
although the mutation AA124–125 reduces mhtt aggrega-
tion signiﬁcantly. In contrast, the mutant htt-N233-82Q
D121–122 is associated with activation of apoptotic pro-
cesses, neuronal cell death and increased aggregation.
There is the possibility that the toxic effect of D121–122 is
not due to the enhanced cleavage of htt-N233-82Q. The
speciﬁc mutation D121–122 could alter the N-terminal
fragment stability or the protein conformation with a sub-
sequent impact of interaction with other cellular proteins.
D121–122 may also inﬂuence the N-terminal htt cleavage
site, whereas a new C-terminus is generated leading to an
alternative toxic fragment.
The R6/2 and N171-82Q mouse models of HD
expressing short N-terminal fragments of mhtt produce a
severe phenotype of HD indicating that mhtt N-terminal
fragments are toxic in vivo (Mangiarini et al. 1996;
Schilling et al. 1999). Interestingly, an HD mouse model
expressing the ﬁrst 117 aa of mhtt did not show an HD
phenotype despite neuronal inclusions (Slow et al. 2005).
Previously, it was shown that htt can be endogenously
cleaved at aa 167 releasing an N-terminal fragment named
cp-2 (distinct from cp-B). Deletion of the cp-2 site almost
completely prevents mhtt (N511-52Q) induced toxicity in
neuronal HT22 cells suggesting that this speciﬁc fragment
is toxic (Ratovitski et al. 2009). In this study, we compared
the toxicity of mhtt proteins with different protein size and
identical polyglutamine lengths by measurement of effec-
tor caspase activities and neuronal cell viability. Our
results demonstrate that htt-N171-82Q is toxic in cells
compared to htt-N233-82Q and htt-N120-82Q. All of this
data suggest that cellular toxicity is mediated by mhtt
N-terminal fragments of speciﬁc size. For example, the
processing of the amyloid precurser protein (APP) by the
c-secretase generates the Aß42- and Aß40-peptides,
whereas the Aß42-peptide is more toxic in vivo suggesting
that a difference in two aa mediates toxicity (Iijima et al.
2004). Further investigation of the mechanisms by which
N-terminal fragments of speciﬁc size induce toxicity
should help to understand the underlying molecular path-
ways in HD.
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